Date: 2014-04-29
Type of information: Development agreement
Compound: NAV rAAVrh10 vector
Company: AAVLife (France) RegenX Biosciences (USA - MD)
Therapeutic area: Rare diseases - Neurodegenerative diseases
Type agreement: development commercialisation
Action mechanism:
Disease: Friedreich's Ataxia
Details: * On April 29, 2014, RegenX Biosciences has announced that the company has entered into an agreement with AAVLife for the development and commercialization of products to treat Friedreich\'s ataxia (FA) using NAV technology. Under the terms of the Agreement, RegenX granted AAVLife an exclusive worldwide license, with rights to sublicense, to deliver RegenX\'s NAV rAAVrh10 vector via non CNS routes to treat FA in humans. In addition, AAVLife was granted an option to obtain a non-exclusive worldwide license to additional NAV vectors for CNS delivery for the treatment of FA in humans. In return for these rights, RegenX receives payments in the form of up-front and on-going fees, certain milestone fees and royalties on net sales of products incorporating NAV vectors. RegenX would also receive a share of any sublicensing revenues. "RegenX has been engaged with the team at AAVLife, including its stakeholders like the Friedreich\'s Ataxia Research Alliance (FARA), since first becoming aware of their gene therapy research results and during the company\'s process of formation. We are pleased to formally continue our collaboration with a team who has the leadership, expertise, resources, and commitment to patients that is required in order to develop innovative treatments for patients with FA through the application of NAV technology,\" said Ken Mills, President and CEO of RegenX.
Financial terms:
Latest news:
